|
Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC). Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC). conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC). Clinical research trials and Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC). medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC).. Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC). Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC). clinical trial. Subjects typically recieve the finest healthcare available for their Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC). condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC). Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC).
Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC).
For Condition: Non-small cell lung cancer
Status: No longer recruiting
Sponsor(s): Sponsor Name Pending ,
Synopsis: The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: (ALL of these criteria must be met in order to be eligible for this study) - Written informed consent - At least 18 years old - Patients with advanced non-small cell lung cancer (NSCLC). - 4 Patients who have received one previous chemotherapy for NSCLC. - Full recovery from previous chemotherapy. - Presence of either measurable or non-measurable disease by radiologic study or physical examination. - At least 3 weeks since last major surgery (a lesser period is acceptable if deemed in the best interest of the patient). - At least 24 hours since prior radiotherapy providing that marked bone marrow suppression is NOT expected. Patients who have received radiotherapy must have recovered from any reversible side effects (e.g. nausea and vomiting). - Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function. EXCLUSION CRITERIA: (NONE of these criteria can be met in order to be eligible for this study.) - Symptoms of brain metastasis (cancer spreading to the brain), requiring treatment with steroids. - Active infection. - Severe medical problems other than the diagnosis of NSCLC, that would limit the ability of the patient to follow study guidelines or expose the patient to extreme risk. - Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of NSCLC. - Use of investigational drug within 30 days prior to the first dose of study medication. - Women who are pregnant or lactating. - Patients of child-bearing potential refusing to practice adequate birth control methods. - Patients with conditions which might alter absorption of an oral drug.
Total Enrollment:
Location and Contact Information:
Study Site
Capa-Istanbul, , 34280
Turkey
Study Site
Strasbourg, , 67098
France
Study Site
Edegem, , 2650
Belgium
Study Site
Verona, , 37126
Italy
Study Site
Koebenhavn, , 2100
Denmark
Study Site
Moscow, , 15478
Russian Federation
Study Site
Ceske Budejovice, , 37087
Czech Republic
Study Site
Gauting Bei Muenchen, , 82131
Germany
Study Site
Berlin, , 14109
Germany
Study Site
Groningen, , 9728
Netherlands
Study Site
Sydney, Nova Scotia, B1P 1P3
Canada
Study Site
St Petersburg, , 197022
Russian Federation
Study Site
Singapore, , 119074
Singapore
Study Site
Adelaide, South Australia, 5042
Australia
Study Site
Vilnius, , Lt-2021
Lithuania
Study Site
Szamarzewskiego, , 62
Poland
Study Site
Helsinki, , 00290
Finland
Study Site
Madrid, , 28040
Spain
Study Site
Izmir, , 35100
Turkey
Study Site
Zurich, , 8091
Switzerland
Study Site
Strasbourg, , 67100
France
Study Site
Roma, , 00149
Italy
Study Site
Lisboa, , 1769-001
Portugal
Study Site
Hertogenbosch, , 5211
Netherlands
Study Site
Leipzig, , 04207
Germany
Study Site
HEERLEN, , 6419
Netherlands
Study Site
Regensburg, , 93049
Germany
Study Site
Russia, , 603000
Russian Federation
Study Site
Wellington, , 6002
New Zealand
Study Site
Madrid, , 28034
Spain
Study Site
Tel Hashomer, , 52621
Israel
Study Site
Athens, , 11526
Greece
Study Site
Lvov, , 79031
Ukraine
Study Site
LIEGE, , 4000
Belgium
Study Site
Leicester, , LE1 5WW
United Kingdom
Study Site
Tel Aviv, , 64239
Israel
Study Site
Dundee, , DD1 9SY
United Kingdom
Study Site
Johannesburg, , 2193
South Africa
Study Site
Surrey, , GU2 5XX
United Kingdom
Study Site
Odense, , 5000
Denmark
Study Site
Pretoria, , 0075
South Africa
Study Site
Sainte-Foy, Quebec, G1V 4G5
Canada
Study Site
Moscow, , 129128
Russian Federation
Study Site
Torino, , 10126
Italy
Study Site
Adelaide, South Australia, 5000
Australia
Study Site
Hamburg, , 21075
Germany
Study Site
Moscow, , 117837
Russian Federation
Study Site
La Laguna, , 38320
Spain
Study Site
Praha, , 14059
Czech Republic
Study Site
Toronto, Ontario, M5G 2C4
Canada
Study Site
Cape Town, , 7506
South Africa
Study Site
Taipei, , 11217
Taiwan, Province of China
Study Site
Treuenbrietzen, , 14929
Germany
Study Site
THESSALONIKI, , 54351
Greece
Study Site
Valencia, , 46009
Spain
Study Site
Munich, , 80336
Germany
Study Site
Athens, , 15669
Greece
Study Site
Moscow, , 115478
Russian Federation
Study Site
Caen, , 14021
France
Study Site
Be'er Sheva, , 84101
Israel
Study Site
Csorna, , 9300
Hungary
Study Site
Budapest, , 1529
Hungary
Study Site
Quezon City, , 1100
Philippines
Study Site
Toronto, Ontario, M6R 1B5
Canada
Study Site
Herlev, , 2730
Denmark
Study Site
Montreal, Quebec, H3A 1A1
Canada
Study Site
Bad Berka, , 99437
Czech Republic
Study Site
Roentgena, , 02-781
Poland
Study Site
Montreal, Quebec, J4V 2H1
Canada
Study Site
Madrid, , 28007
Spain
Study Site
Kladno, , 14059
Czech Republic
Study Site
Delft, , 2625
Netherlands
Study Site
Glasgow, , G4 0SF
United Kingdom
Study Site
Innsbruck, , A-6020
Austria
Study Site
Athens, , 15669
Greece
Study Site
Patras, , 26500
Greece
Study Site
Dijon, , 21034
France
Study Site
Oshawa, Ontario, L1G 2B9
Canada
Study Site
Turku, , 20520
Finland
Study Site
Belfort, , 90016
France
Study Site
Thunder Bay, Ontario, P7A 7T1
Canada
Study Site
Wien, , A-1220
Austria
Study Site
Porto, , 4200
Portugal
Study Site
Samara, , 443066
Russian Federation
Study Site
Portuense, , 00149
Italy
Study Site
Riga, , Lv-1079
Latvia
Study Site
Cape Town, , 7925
South Africa
Study Site
Pontevedra, , 36071
Spain
Study Site
Toulin Naval, , 83800
France
Study Site
Vesoul, , 70014
France
Study Site
London, , SE1 9RT
United Kingdom
Study Site
Ashkelon, , 78306
Israel
Study Site
Szamarzewskiego, , 60-569
Poland
Study Site
Nottingham, , NG5 1PB
United Kingdom
Study Site
Miskolc, , 3529
Hungary
Study Site
Taipei, , 10016
Taiwan, Province of China
Study Site
Albertoni, , 40138
Italy
Study Site
Leeuwarden, , 8934
Netherlands
Study Site
Bangkok, , 10400
Thailand
Study Site
Crete, , 71201
Greece
Study Site
Toronto, Ontario, M4C 3E7
Canada
Study Site
Cape Town, , 7530
South Africa
Study Site
Lerida, , 25198
Spain
Study Site
Bloemfontein, , 9301
South Africa
Study Site
Riga, , Lv-1002
Latvia
Study Site
Orbassano, , 10043
Italy
Study Site
Brunamonti, , 06122
Italy
Study Site
Barakaldo, , 48903
Spain
Study Site
Brasschaat, , 2930
Belgium
Study Site
Valencia, , 46009
Spain
Study Site
Jaen, , 23007
Spain
Study Site
Brussels, , 1200
Belgium
Study Site
Sassari, , 07100
Italy
Study Site
Port Elizabeth, , 6006
South Africa
Study Site
Tau-Yuan Shian, , 333
Taiwan, Province of China
Study Site
Burgos, , 09005
Spain
Study Site
Roentgena, , 02-781
Poland
Additional Information:
Study ID Numbers: 104864-A/387;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00049998
Other Non-Small Cell Lung Cancer Studies:
1. Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
2. Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases
3. Tarceva Surgery for Resectable Stage IIIA(N2) Non-Small-Cell Lung Cancer
4. National Lung Screening Trial (NLST)
5. GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Related Studies:
Other Non-small cell lung cancer Clinical Trials
Other Clinical Trials
Other Miskolc Clinical Trials
Oral Investigational Drug Vs. Approved Intravenous Treatment In Pretreated, Advanced Non-Small Cell Lung Cancer (NSCLC).
|
|
|
|
|
|
|
|